Takeda Pharmaceutical (TAK) Gains from Sales and Divestitures (2019 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Gains from Sales and Divestitures of $1.2 million for Q2 2026, down 69.84% year-over-year from $4.0 million in Q2 2025, and down 89.36% quarter-over-quarter from $11.4 million in Q1 2026.
Takeda Pharmaceutical (TAK) Gains from Sales and Divestitures (2019 - 2026) Analysis & Trends
Takeda Pharmaceutical's Gains from Sales and Divestitures history runs 8 years deep, the most recent figure standing at $1.2 million for Q2 2026.
- In Q2 2026, Gains from Sales and Divestitures fell 69.84% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $17.2 million (down 13.31% YoY), while the FY2026 annual figure was $20.4 million, down 30.93% from the prior year.
- Gains from Sales and Divestitures for Q2 2026 stood at $1.2 million, down from $11.4 million in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $27.4 million in Q1 2024, with the low at -$152337.4 in Q3 2023.
- The 5-year median for Gains from Sales and Divestitures is $2.5 million (2024), against an average of $6.2 million.
- Peak annual rise in Gains from Sales and Divestitures reached 4294.87% in 2023, while the deepest fall reached 115.25% in 2023.
- Takeda Pharmaceutical's Gains from Sales and Divestitures stood at $999194.4 in 2022, then jumped by 1040.18% to $11.4 million in 2023, then sank by 65.24% to $4.0 million in 2024, then plunged by 41.25% to $2.3 million in 2025, then tumbled by 47.68% to $1.2 million in 2026.
- Business Quant data shows TAK's Gains from Sales and Divestitures at $1.2 million in Q2 2026, $11.4 million in Q1 2026, and $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Mn |
| Jun 30, 2026 | 1.22 Mn |
| Mar 31, 2026 | 11.44 Mn |
| Mar 31, 2026 | 11.44 Mn |
| Dec 31, 2025 | 2.33 Mn |
| Dec 31, 2025 | 2.33 Mn |
| Sep 30, 2025 | 2.25 Mn |
| Sep 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.04 Mn |
| Mar 31, 2025 | 9.41 Mn |
| Mar 31, 2025 | 9.41 Mn |
| Dec 31, 2024 | 3.96 Mn |
| Dec 31, 2024 | 3.96 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Sep 30, 2024 | 2.47 Mn |
| Jun 30, 2024 | 13.41 Mn |
| Jun 30, 2024 | 13.41 Mn |
| Mar 31, 2024 | 27.42 Mn |
| Mar 31, 2024 | 27.42 Mn |